GlaxoSmithKline SAE
BIOC.CA- Latest Trade
- trading higher35.02EGP
- 0
- 0.00%
- As of Jan 29 2023. Values delayed up to 15 minutes
- Day Range
- -- - --
- 52-Week Range
- 18.70 - 45.40
- Previous Close
- 35.02
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 1.54
- Shares Out (Mil)
- 83.51
- Market Cap
- 2,924.67
- Forward P/E
- -99,999.99
- Dividend Yield
- 2.03
Key Statistics
mean rating - analysts
- P/E Excl. Extra Items (TTM)
- 18.75
- Price To Sales (TTM)
- 1.53
- Price To Book (Quarterly)
- 1.33
- Price To Cash Flow (Per Share TTM)
- 14.16
- Total Debt/Total Equity (Quarterly)
- 2.30
- Long Term Debt/Equity (Quarterly)
- 2.30
- Return On Investment (TTM)
- 8.58
- Return On Equity (TTM)
- 5.89
2021 (millions USD)
About GlaxoSmithKline SAE (BIOC.CA)
Company Information
GlaxoSmithKline SAE, a member of Glaxo Group Limited (Britain), is an Egypt-based company engaged in manufacturing, packaging, marketing, sale and distribution of pharmaceutical products. In addition, it manufactures and distributes several other licensed products from other companies. The Company's pharmaceutical product range includes treatments for asthma, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer. Glaxo Smith Kline has a 99.66% interest in Amoun Pharmaceutical Industries Company, which is an Egypt-based pharmaceuticals and medical appliances manufacturer.
Address
No 46, Block (J), Boomerang Building first section city centre,Fifth district New CairoCAIRO,
11835
Egypt
Industry
Biotechnology & Drugs
Executive Leadership
- Amro Mamdouh Abdul Majid
- Chairman of the Board, Managing Director, representing Glaxo Group Ltd. and Legal Advisor
- Mohammed Amin Ibrahim
- Head of Finance and Executive Member of the Board, representing Glaxo Group Ltd.
- Tharwat Gergis Habib Abdul Shahid
- General Counsel, Non-Executive Member of the Board
- Tariq Abdul Khaliq
- Executive Member of the Board, representing Glaxo Group Ltd.
- Ashraf Mohammed Mansour Ibrahim
- Executive Member of the Board, representing Glaxo Group Ltd. and Medical and Regulatory Director
- Khalid Najem
- Director of Sales
- Adel Mahmoud Amer Yousef
- Director of Investor Relations
- Mohammed Azzam
- Finance Manager
- Hisham Badr
- Head of Vaccines
- Khalid Morsi
- Compliance Manager
- Omnia Nabil
- Business Development Director
- Laila Shaker
- Government Affairs and Communication Manager
- Sherine Al Ansari
- Non-Executive Member of the Board, representing Al Ahly Societe General Bank
- Mounir Ghabour Hanna
- Non-Executive Member of the Board
- Subramanian Madhavan
- Additional Independent Director
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,927.60 | 0.12% |
| Copper | 783.30 | 1.20% |
| Brent Crude Oil | 86.66 | -- |
| CBOT Soybeans | 1,512.25 | 0.74% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,070.56 | 0.25% |
| Euro STOXX 50 | 4,178.01 | 0.10% |
| FTSE 100 | 7,765.15 | 0.05% |
| Nikkei 225 | 27,382.56 | 0.07% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes